Skip to main content

NDA Submitted for OTC Zegerid

Schering-Plough Announces Filing of U.S. Application for OTC Zegerid

KENILWORTH, N.J., March 11, 2008 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced a submission to the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for Zegerid (omeprazole/sodium bicarbonate) in the dosage strength of 20 mg of omeprazole as a branded over-the-counter (OTC) product to treat frequent heartburn.

The NDA was submitted under the terms of a license agreement with Santarus, Inc. of San Diego, Calif., which was signed in October 2006 for the exclusive U.S./Canadian rights to market OTC Zegerid proton pump inhibitor (PPI) products using Santarus' patented technology.

"Schering-Plough is looking forward to working with the FDA to bring this prescription product to consumers as an OTC treatment for frequent heartburn," said John E. O'Mullane, B.Sc., Ph.D., group vice president, Research and Development, Schering-Plough Consumer Health Care. "When approved, Zegerid will be a valuable addition to our expanding portfolio of gastrointestinal OTC products such as MiraLAX, which was launched last year for the treatment of occasional constipation."

Under the agreement with Santarus, Schering-Plough is responsible for the development, manufacturing and commercialization of Zegerid (omeprazole/sodium bicarbonate) OTC products for heartburn-related indications in the U.S. and Canada. Santarus continues to manufacture, promote and sell its Zegerid (omeprazole/sodium bicarbonate) prescription products in both 20 mg and 40 mg dosage strengths of omeprazole for the U.S. prescription market for PPI products.

Product Description

Zegerid (omeprazole/sodium bicarbonate) contains omeprazole, a proton pump inhibitor (PPI), and sodium bicarbonate, which raises the gastric pH and thus protects omeprazole from acid degradation.

Important Safety Information about Zegerid

The most frequently reported adverse events with Zegerid are headache, diarrhea, and abdominal pain. Symptomatic response to therapy does not preclude the presence of gastric malignancy. Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long term with omeprazole.

Zegerid contains sodium bicarbonate. This should be taken into consideration for patients on a sodium-restricted diet.

Zegerid is contraindicated in patients with known hypersensitivity to any component of the formulation.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the future regulatory approval and potential for Zegerid. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward- looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering- Plough's Securities and Exchange Commission filings, including Part I, Item IA. "Risk Factors" in Schering-Plough's 2007 10-K/A.

CONTACT: Media, Steve Galpin, Jr., +1-908-298-7415, or Julie Lux, +1-908-298-4774; or Investor, Alex Kelly, or Robyn Brown, +1-908-298-7436

Web site: http://www.schering-plough.com//

Company News On-Call: http://www.prnewswire.com/comp/777050.html/

Ticker Symbol: (NYSE:SGP)

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: March 2008

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.